Ambrx Biopharma Inc (AMAM) Return on Equity ROE from the third quarter 2023 to third quarter 2022 and annually, average high and low, overall ranking from Sep 30 2023 to Sep 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ambrx Biopharma Inc   (NASDAQ: AMAM)

Ambrx Biopharma Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Ambrx Biopharma Inc in the third quarter 2023?
Ambrx Biopharma Inc recorded a cumulative net loss of $-134 million during 12 months ending in the third quarter 2023, resulting in a negative return on equity (ROE) of -67.63%.

Within the Biotechnology & Pharmaceuticals industry 83 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2023 from 3098 to 3403.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Equity Change 70.84 % 31.8 % -3.88 % -38.87 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -134 -127 -138 -145 -135
Return On Equity (TTM) -67.63 % -73.16 % -87.12 % -90.7 % -75.76 %
AMAM's Total Ranking # 3403 # 3098 # 0 # 0 #
Equity (TTM) in Millions 242 250 183 118 142
Seq. Equity Change -3.19 % 37.13 % 54.94 % -16.94 % -25.31 %
Seq. Net Income Change - - - - -

Back to AMAM Management Effectiveness >> AMAM's 5 Years Annual ROE >> Compare AMAM ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 84
Sector # 542
Overall # 3403

Return On Equity Statistics
High Average Low
-35.95 %
-66.82 %
-96.88 %
(Dec 31 2021)   (Jun 30 2023)





AMAM Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021


Total Equity in Millions 118 190 0 0 0
Y / Y Equity Change -37.96 % - - - -
Net Income in Millions -78 -68 0 0 0
Y / Y Net Income Change - - - - -
Return On Equity -66.18 % -35.95 % - - -

Back to AMAM Management Effectiveness >> AMAM's 5 Years Annual ROE >> Compare AMAM ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
AMAM's' Return on Equity at Yahoo Finance
AMAM's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for AMAM's Competitors
Subscribers only: Roe for Ambrx Biopharma Inc 's Suppliers
Subscribers only: Return On Equity for AMAM's Customers




Companies with similar Return On Equity at Sep 30 2023, within Healthcare Sector ROE

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.